Click Here to download a MS Word copy of the program.

TENTATIVE PROGRAM

8:15 - 8:30 Introduction and overview of Conference
Dr. Marc Dichter - University of Pennsylvania

Molecular targets for drug development for neuroprotection

8:30 - 9:00 Ion Channels and Transporters as Targets for Neuroprotection - one set of targets
(Role of ionotropic glutamate receptors - AMPA, NMDA, kainate -- and K+, Ca++, Na+ channels as potential targets)
Dr. Michael Rogawski - NINDS

9:00 - 9:30 Apoptosis - a second target
Dr. Eugene Johnson - Washington University

9:30 -10:00 Other potential targets - Metabolic issues, oxidative damage, free radicals, blood flow, other ions, thermal, etc.
Dr. Norman Delanty - University of Dublin

10:00 - 10:30 Roundtable discussion/directed commentaries: Similarities and differences among different insults - Is it rational to mix acute and chronic protection paradigms?

10:30 - 10:45 Coffee break

Neuroprotection from animal models to clinical trials
(For each disease: what is the model, why is it appropriate, what are its limitations, what assays are utilized, what strategies are employed, what results have been obtained - brief reviews, approximately 20 min each.)

10:45 - 11:15 Animal models of global and focal ischemia
Dr. Myron Ginsberg - University of Miami

11:15 - 11:45 Clinical trials of thrombolytic agents - lessons learned
Dr. Steven Levine - Mt. Sinai School of Medicine

11:45 - 12:15 Neuroprotection trials in stroke
Dr. Scott Kasner - University of Pennsylvania

12:15 - 12:45 Discussion

12:45 - 1:45 Lunch

1:45 - 2:15 Perioperative brain injury trials
Dr. Mark Newman - Duke University

2:15 - 2:45 Traumatic brain and spinal cord injury - Animal models
Dr. Tracy McIntosh - University of Pennsylvania

2:45 - 3:15 Traumatic brain and spinal cord injury - Clinical trials
Dr. Paul Vespa - UCLA

3:15 - 3:30 Discussion

3:30 - 3:45 Coffee Break

3:45 - 4:15 Status epilepticus/refractory epilepsy - preventing damage and protecting against epileptogenesis - Animal models
Dr. Asla Pitkanen - University of Kupio, Finland

4:15 - 4:45 Status epilepticus/refractory epilepsy - Clinical trials
Dr. Susan Herman - University of Pennsylvania

4:45 - 5:00 Roundtable discussion: Preventing damage and preventing secondary consequences of repair processes (e.g. preventing epileptogenesis)

5:00 - 5:45 Roundtable discussion/directed commentaries: Why haven't animal trials served as good predictors of human trials?

7:00 - 11:00 Evening reception

DAY 2 - Friday, January 24, 2003

8:30 - 9:00 Neonatal models - Perinatal encephalomalacia - Animal models
Dr. Frances Jensen - Harvard University

9:00 - 9:30 Neonatal models - Clinical trials
Dr. Donna Ferriero - University of California, San Francisco

9:30 - 10:00 Alzheimer's disease - Animal models/Clinical trials
Dr. Steven Dekosky - University of Pittsburgh

10:15 - 10:45 Parkinson's disease - Animal models/Clinical trials
Dr. Matthew Stern - University of Pennsylvania

10:45 - 11:15 Amyotrophic lateral sclerosis disease - Animal models/Clinical trials
Dr. Jeffrey Rothstein - Johns Hopkins

11:15 - 11:45 The neurodegenerative components of psychoses
Dr. Husseini Manji - NIMH

11:45 - 12:15 Roundtable Discussion: Relationship between neuroprotection in acute disorders vs chronic conditions - will one drug/drug combination/strategy likely work for both situations?

12:15 - 1:30 Lunch

New strategies for clinical trials in neuroprotection - Dr. Jacqueline French - moderator

1:30 - 2:00 Using common approaches to different neurological diseases
Dr. Howard Weiner - Brigham & Women's Hospital, Harvard

2:00 - 2:30 Screening for new neuroprotective compounds
Dr. Jill Heemsderk - NINDS

2:30 - 3:00 Proof of principle trials - which paradigm to choose?
Academic investigator perspective: Dr. Justin Zivin - University of California, San Diego

3:00 - 3:30 Proof of principle trials - which paradigm to choose?
Industry perspective: Dr. Roy Twyman - Johnson & Johnson

3:30 - 3:45 Coffee Break

3:45 - 4:15 Use of imaging as a surrogate marker
Dr. Elias Melhem - University of Pennsylvania

4:15 - 4:45 Other potential surrogate markers
Dr. Robert Neumar - University of Pennsylvania

4:45 - 5:15 Discussion

DAY 3 - Saturday, January 25, 2003

8:30 - 9:00 FDA requirements for different indications
Dr. Russell Katz - FDA

9:00 - 9:30 What kinds of preclinical data are needed to proceed to a clinical trial?
Dr. W. Frost White - Pfizer

9:30 - 10:00 Increasing the chances of success in neuroprotection trials
Dr. John Marler - NINDS

10:00 - 10:30 Discussion - Dr. Bernard Ravina - NINDS

10:30 - 10:45 Coffee Break

10:45 - 11:15 The challenge of accruing patients in the acute settings - time windows, informed consent, medical personnel, etc.
Dr. Brett Skolnick, Novo-Nordisk

11:15 - 11:45 Ethics and logistics of neuroprotection trials
Dr. Greg Fromell - University of Pennsylvania

11:45 - 12:15 Roundtable discussion/directed commentaries: Involvement of clinicians outside neurology/neurosurgery (ED, anesthesiology, surgery, pediatric surgery, neonatology, etc.)
Dr. Michael McGarvey - University of Pennsylvania

12:15 - 12:30 Where do we go from here in neuroprotection trials?
Dr. Marc Dichter - University of Pennsylvania
ADJOURN